Mindaugas Jievaltas

A. Mickeviciaus Str. 9
Kaunas, KU LT44307, Lithuania

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Rare Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report and Review of the Literature.

Rare Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report and Review of the Literature.

Journal: Journal of clinical medicine

Published: February 02, 2026

Comparison of prostate cancer diagnostic models based on PCA3 and TMPRSS2:ERG RNA biomarkers from post-DRE and non-DRE urine specimens.

Comparison of prostate cancer diagnostic models based on PCA3 and TMPRSS2:ERG RNA biomarkers from post-DRE and non-DRE urine specimens.

Journal: World journal of urology

Published: January 27, 2026

The Role of Untraceable Sentinel Lymph Nodes in Prostate Cancer Patients Undergoing Radical Prostatectomy and Pelvic Lymph Node Dissection: Insights from an Ongoing Prospective Study.

The Role of Untraceable Sentinel Lymph Nodes in Prostate Cancer Patients Undergoing Radical Prostatectomy and Pelvic Lymph Node Dissection: Insights from an Ongoing Prospective Study.

Journal: Journal of clinical medicine

Published: November 25, 2025

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: August 18, 2025

Rare and Aggressive Disease: Urinary Bladder Leiomyosarcoma.

Rare and Aggressive Disease: Urinary Bladder Leiomyosarcoma.

Journal: Journal of clinical medicine

Published: June 27, 2025

Inflammatory markers in prostate cancer: potential roles in risk stratification and immune profiling.

Inflammatory markers in prostate cancer: potential roles in risk stratification and immune profiling.

Journal: Journal of immunotoxicology

Published: April 29, 2025

Performance of PCA3 and TMPRSS2:ERG Within the Prostate Cancer Prevention Trial Risk Calculator Version 2 in a Lithuanian Cohort.

Performance of PCA3 and TMPRSS2:ERG Within the Prostate Cancer Prevention Trial Risk Calculator Version 2 in a Lithuanian Cohort.

Journal: Research and reports in urology

Published: December 11, 2024

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 16, 2024

Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients.

Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients.

Journal: Abdominal radiology (New York)

Published: August 28, 2024

Primary Renal Angiosarcoma: Rare Tumour with Lethal Outcomes.

Primary Renal Angiosarcoma: Rare Tumour with Lethal Outcomes.

Journal: Medicina (Kaunas, Lithuania)

Published: April 16, 2024

Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.

Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.

Journal: The Prostate

Published: December 03, 2023

Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania.

Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania.

Journal: Medicina (Kaunas, Lithuania)

Published: September 05, 2023

Showing 1-12 of 42

Last Updated: 09/26/2026